Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE-2: NT-0796 as Adjunct to Semaglutide in Obesity
NCT07220629Phase 2Completed
- Sponsor
- Rezera
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruvonoflast in obesity, sponsored by Rezera. Started Oct 2025; status: completed.
02
Drugs
ruvonoflast
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07220629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220629.